ClinicalTrials.gg
CompletedNCT07508462Updated Apr 2, 2026

A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

A Phase 1 interventional study of Ammoxetine hydrochloride enteric-coated tablets and Ammoxetine hydrochloride enteric-coated tablets in Healthy Participants, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2024, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single-dose, randomized, open-label, three-sequence, three-period crossover clinical trial to evaluate the effect of high-fat and low-fat meals on the pharmacokinetics of ammoxetine hydrochloride enteric-coated tablets in healthy subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-45 years (inclusive), both male and female subjects;
  2. Body weight ≥ 45.0 kg (female) or 50.0 kg (male), with (BMI) between 19.0 kg/m² and 28.0 kg/m² (inclusive);
  3. Results of medical history, vital signs, physical examination, laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and other relevant tests), and chest X-ray examination are normal or abnormal but without clinical significance;
  4. Subjects with interval using Fridericia's formula exceeding the (male ≥450 ms or female ≥460 ms), or with abnormal findings considered by the study physician, or with a history of arrhythmias or syncope associated with arrhythmias, or using a pacemaker.
  5. Voluntarily sign the form and be willing to comply with the protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of allergies (allergic to two or more types of drugs, foods, or pollen);
  2. Subjects suffering from psychiatric disorders, hepatic or renal diseases, gastrointestinal diseases, neurological diseases, or other systemic diseases;
  3. Subjects with orthostatic hypotension;
  4. Subjects with a 12-lead interval exceeding the (male ≥450 ms or female ≥460 ms), or with abnormal ECG findings considered by the study physician, or with a history of arrhythmias or syncope associated with arrhythmias, or using a pacemaker. Note: Diseases include, but are not limited to: heart failure; hypokalemia; atrial fibrillation, atrial flutter, premature atrial contractions, premature ventricular contractions, non-sustained or sustained ventricular tachycardia; bradycardia or sick sinus syndrome; personal or family history of any cardiac conduction abnormalities; personal or family history of long QT syndrome (LQTS); or family history of sudden death;
  5. Subjects with a history of smoking or alcohol abuse (consumption of 14 units of alcohol per week within the 4 weeks prior to screening: 1 unit = 285 mL beer, or 25 mL spirits, or 150 mL wine; daily smoking ≥ 5 cigarettes) or other substance or drug abuse within the past year;
  6. Subjects with a positive alcohol breath test or positive urine drug screen during the screening period;
  7. Subjects who have donated or lost more than 400 mL of blood within the 8 weeks prior to screening;
  8. Subjects who have participated in other drug clinical trials within the 3 months prior to screening;
  9. Subjects who habitually consume excessive amounts of caffeinated beverages or foods within the 4 weeks prior to screening, such as coffee, tea, chocolate, cola, or Red Bull (daily caffeine intake not exceeding 6 units). 1 caffeine unit = 1 cup of coffee (177.4 mL) = 2 cans of cola (354.9 mL) = 1 cup of tea (354.9 mL) = 1/2 cup of energy drink = 85 g chocolate;
  10. Subjects who have used medications that alter the activity of liver enzymes (Cytochrome P450 2C19 and Cytochrome P450 3A4) within the 4 weeks prior to screening, such as dexamethasone, ketoconazole, rifampicin, or omeprazole;
  11. Subjects who have consumed dragon fruit, mango, shaddock, grapefruit, lime, star fruit, pomegranate, or any foods or beverages prepared from these fruits within the 7 days prior to screening;
  12. Subjects who have used prescription drugs, over-the-counter medications (except for occasional use of acetaminophen and nasal sprays), herbal remedies, vitamins, or minerals within the 2 weeks prior to screening, or for whom the of prior medications (based on the longest half-life) is less than 5 half-lives before screening;
  13. Subjects using any psychiatric medications or psychoactive substances;
  14. Pregnant or lactating women, or female subjects with a positive pregnancy test during the screening period;
  15. Subjects considered by the investigator to have any factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Fasting conditions

    Period in which subjects receive a single oral dose of ammoxetine hydrochloride enteric-coated tablets in fasting condition.

    Drug: Ammoxetine hydrochloride enteric-coated tablets

  • Experimental
    High-fat fed conditions

    Period in which subjects receive a single oral dose of ammoxetine hydrochloride enteric-coated tablets in high-fat fed condition.

    Drug: Ammoxetine hydrochloride enteric-coated tablets

  • Experimental
    Low-fat fed conditions

    Period in which subjects receive a single oral dose of ammoxetine hydrochloride enteric-coated tablets in low-fat fed condition.

    Drug: Ammoxetine hydrochloride enteric-coated tablets

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters

    Maximum plasma concentration (Cmax)

    Time frame: up to 48 hours

  2. PK parameters

    Area under the plasma concentration-time curve extrapolated to infinity (AUC0-inf)

    Time frame: up to 48 hours

  3. PK parameters

    Area under the concentration-time curve from zero to the last measurable time (AUC0-t)

    Time frame: up to 48 hours

07

Study locations

1 site
  • The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital
    Shijiazhuang, Hebei 050035, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jun 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 2, 2026
StartActual
May 30, 2024
Primary completionActual
Jun 17, 2024
CompletionActual
Aug 2, 2024
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07508462
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
May 30, 2024
Primary completion
Jun 17, 2024
Completion
Aug 2, 2024
Last update
Apr 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ammoxetine

Start the discussion